News & Presentations

News Releases

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
May 10, 2022
Tarsus to Present at Bank of America 2022 Healthcare Conference
May 06, 2022
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
May 05, 2022
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock
May 03, 2022
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock
May 02, 2022
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year
May 02, 2022
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Apr 29, 2022
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
Apr 26, 2022
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements
Mar 14, 2022
Tarsus to Present at Upcoming Investor Conferences
Mar 09, 2022

Presentations